百奧泰(688177.SH):與百濟神州就貝伐珠單抗簽署授權、分銷、供貨協議
格隆匯 8 月 24日丨百奧泰(688177.SH)公佈,公司與百濟神州有限公司(“百濟神州”)簽署授權、分銷、供貨協議,將公司藥品BAT1706相關知識產權及其在中國地區(包括中國大陸、香港特別行政區、澳門特別行政區、台灣,下同)的產品權益有償許可給百濟神州。
首付款及里程碑款總金額最高至1.65億美元,其中包括2000萬美元首付款、累計不超過14500萬美元里程碑付款和兩位數百分比的銷售提成。
協議履行期限:自協議生效之日起,持續有效至BAT1706(貝伐珠單抗)獲國家藥品監督管理局上市批准之後15年,期限屆滿後,雙方可共同協商延長。
BAT1706是百奧泰根據中國NMPA、美國FDA和歐盟EMA生物類似藥相關指導原則開發的貝伐珠單抗注射液,是一款靶向血管內皮生長因子(VEGF)的人源化單克隆抗體。可以特異性地與VEGF結合,阻斷VEGF與其受體結合從而減少新生血管生成誘導現有血管的退化從而抑制腫瘤生長。貝伐珠單抗原研藥在歐美獲批的適應症包括轉移性結直腸癌、晚期非鱗狀非小細胞肺癌、腎細胞癌、卵巢癌、宮頸癌、惡性膠質瘤等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.